Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. The invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. One such foreign DNA sequence is modified CEA nucleic acid.
Type:
Grant
Filed:
April 9, 2003
Date of Patent:
August 31, 2010
Inventors:
Mark Parrington, Linong Zhang, Benjamin Rovinski, Linda R. Gritz, Patricia Greenhalgh
Abstract: This document includes methods and materials for enriching and detecting cancer markers. For example, this document includes methods and materials for enriching methylated mammalian nucleic acid from stool samples.
Type:
Grant
Filed:
January 23, 2008
Date of Patent:
August 31, 2010
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: Methods and compositions are described for classifying cells and/or peptides that associate or bind with a particular characteristic pattern to a plurality of cells or cell lines. Aspects of the invention also include the use of peptide(s) having an appropriate binding characteristic to deliver a drug to a cell or cell population.
Type:
Grant
Filed:
March 9, 2007
Date of Patent:
August 24, 2010
Assignee:
The Board of Regents of the University of Texas System
Abstract: Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed.
Type:
Grant
Filed:
November 25, 2009
Date of Patent:
August 24, 2010
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Mark I. Greene, Ramachandran Murali, Hongtao Zhang, Mark Richter, Alan Berezov, Qingdu Liu, Jinqiu Chen
Abstract: The invention relates to a method for assessing the proliferative state of cells in a human or non human biological sample, comprising using Chromatin Assembly Factor-1 (CAF-1 in short) subunits as proliferation markers. Application for cancer prognosis or diagnosis and monitoring tumor response in therapy.
Type:
Grant
Filed:
August 28, 2006
Date of Patent:
August 24, 2010
Assignees:
Institut Curie, Centre National de la Recherche Scientifique (CNRS), Universite Pierre et Marie Curie
Inventors:
Genevieve Almouzni, Sophie E. Polo, Stamatios E. Theocharis, Philippe Vielh
Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.
Type:
Grant
Filed:
July 2, 2007
Date of Patent:
August 17, 2010
Assignee:
Celera Corporation
Inventors:
Bruno Domon, Steve Ruben, Charles E. Birse, Yeoun Jin Kim, Tao He, Ian McCaffery
Abstract: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.
Type:
Grant
Filed:
August 12, 2005
Date of Patent:
July 27, 2010
Assignee:
Active Biotech, AB
Inventors:
Gunnar Hedlund, Göran Forsberg, Marie Wallén-öhman
Abstract: A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization.
Type:
Grant
Filed:
September 22, 2008
Date of Patent:
July 20, 2010
Assignee:
Agensys, Inc.
Inventors:
Mary Faris, Pia M. Challita-Eid, Rene S. Hubert, Daniel E. H. Afar, Arthur B. Raitano, Wangmao Ge, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Aya Jakobovits
Abstract: The present invention relates to the use of an active ingredient and to a method for the prevention or treatment of tumors, the diagnostic detection of disorders associated with these tumors, and pharmaceutical compositions and kits related thereto.
Type:
Grant
Filed:
April 15, 2003
Date of Patent:
July 20, 2010
Assignee:
Proteosys AG
Inventors:
Michael Cahill, Wojciech Wozny, André Schrattenholz, Helmut Klocker, Hermann Rogatsch
Abstract: Methods for diagnosing or detecting cancerous prostate tissue. A panel of 8 specific marker genes are provided. The overexpression of some of these marker genes compared to their expression in normal prostate tissue and the underexpression of the rest of these marker genes are indicative of cancerous prostate tissue. By using these 8 marker genes as a diagnostic tool, smaller tissue samples, such as those obtained by core needle biopsies can be used.
Abstract: The invention relates to a polypeptide or part thereof which inhibits the apoptotic activity of the tumor suppressor protein p53, and includes screening methods to identify agents which interfere with the activity of the polypeptide.
Type:
Grant
Filed:
March 5, 2008
Date of Patent:
June 29, 2010
Assignees:
Ludwig Institute for Cancer Research, Genome Research Limited, UCL Cruciform Limited
Inventors:
Xin Lu, Patricia Kuwabara, David Selwood
Abstract: Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary of the types of preneoplastic/neoplastic diseases subject to the prognostic methods of this invention are those of gastric mucosa, gallbladder, biliary ducts, and ductal cells of duodenal glands. An exemplary prognostic method comprises comparing the level of MN gene expression product in a tissue sample from the affected subject, with the average MN gene expression product level found in analogous preneoplastic/neoplastic tissue samples; an above average MN gene expression product level indicates poorer prognosis for the subject. MN gene expression products useful in the prognostic methods include MN protein, MN polypeptide, and/or MN nucleic acids.
Type:
Grant
Filed:
February 16, 2009
Date of Patent:
June 22, 2010
Assignee:
Institute of Virology of the Slovak Academy of Science
Inventors:
Matthias Ebert, Christoph Röcken, Silvia Pastorekova, Jan Zavada, Jaromir Pastorek
Abstract: This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides different uses of the monoclonal antibody 8H9 or its derivative.
Type:
Grant
Filed:
March 6, 2003
Date of Patent:
June 22, 2010
Assignee:
Sloan-Kettering Institute for Cancer Research
Abstract: The present invention discloses a method for treating cancer by using hCRMP1 and/or active fragments thereof, as well as the active fragments of hCRMP1 that are capable of inhibiting cell proliferation, invasive activity, and metastasis of cancer. The method can also be used prior to, or in combination with, the administration a chemotherapy agent. A vector capable of expressing an hCRMP1, a variant of hCRMP1, a fragment of hCRMP1 or a variant of a fragment of hCRMP1 is also disclosed.
Type:
Grant
Filed:
March 21, 2008
Date of Patent:
June 22, 2010
Assignee:
Advpharma Inc.
Inventors:
Harn-Jing Terng, Yi-Jen Lee, Woan-Jen Lee
Abstract: A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry.
Type:
Grant
Filed:
December 22, 2009
Date of Patent:
June 15, 2010
Assignee:
AVEO Pharmaceuticals, Inc.
Inventors:
Jie Lin, Bin Feng, Murray Robinson, Feng Jiang, Xiaojian Sun
Abstract: The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer.
Type:
Grant
Filed:
September 1, 1999
Date of Patent:
June 15, 2010
Assignee:
Diadexus, Inc.
Inventors:
Susana Salceda, Yongming Sun, Herve Recipon, Robert Cafferkey
Abstract: Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein are methods that can be used to identify modulators of prostate cancer.
Type:
Grant
Filed:
November 30, 2006
Date of Patent:
June 15, 2010
Assignee:
Cedars-Sinai Medical Center
Inventors:
Daniel E. H. Afar, David Agus, David H. Mack
Abstract: A method for determining whether a patient in need thereof will respond to chemotherapy by screening a suitable sample isolated from the patient for a pre-selected polymorphism present in the VGSC gene.
Abstract: Peptides derived from the peptide CMS-010, which has the formula VAPEEHPTLLTEAPLNPK, are disclosed with their use as pharmaceutical compositions. A method is also disclosed for making a pharmaceutical composition comprising providing a peptide derived from CMS-010 and mixing said peptide with a pharmaceutical acceptable carrier.
Type:
Grant
Filed:
April 25, 2005
Date of Patent:
May 18, 2010
Assignee:
CMS Peptides Patent Holding Company Limited
Abstract: A small percentage of cells within an established tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. The solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. This discovery is the basis for solid tumor stem cell compositions, methods for distinguishing functionally different populations of tumor cells, methods for using these tumor cell populations for studying the effects of therapeutic agents on tumor growth, and methods for identifying and testing novel anti-cancer therapies directed to solid tumor stem cells.
Type:
Grant
Filed:
May 24, 2007
Date of Patent:
May 11, 2010
Assignee:
The Regents of the University of Michigan
Inventors:
Michael F. Clarke, Sean J. Morrison, Max S. Wicha, Muhammad Al-Hajj